[Embryonic stem cells. Future perspectives].
Embryonic stem cells (ES cells) are able to differentiate into any cell type, and therefore represent an excellent source for cellular replacement therapies in the case of widespread diseases, for example heart failure, diabetes, Parkinson's disease and spinal cord injury. A major prerequisite for their efficient and safe clinical application is the availability of pure populations for direct cell transplantation or tissue engineering as well as the immunological compatibility of the transplanted cells. The expression of human surface markers under the control of cell type specific promoters represents a promising approach for the selection of cardiomyocytes and other cell types for therapeutic applications. The first human clinical trial using ES cells will start in the United States this year.
Groebner
M
M
Medizinische Klinik und Poliklinik I, Klinikum der Universität, München-Grosshadern.
David
R
R
Franz
W M
WM
D002478:Cells, Cultured; D017321:Clinical Trials, Phase I as Topic; D003920:Diabetes Mellitus / Q000628:therapy; D053595:Embryonic Stem Cells / Q000637:transplantation*; D006333:Heart Failure / Q000628:therapy; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy; D009206:Myocardium / Q000473:pathology; D010300:Parkinson Disease / Q000628:therapy; D011379:Prognosis; D012038:Regeneration / Q000502:physiology; D013119:Spinal Cord Injuries / Q000628:therapy; D023822:Tissue Engineering / Q000639:trends; D014481:United States